K Number
K131184
Device Name
INTEGRA LICOX PTO2 MONITOR
Date Cleared
2013-08-30

(127 days)

Product Code
Regulation Number
882.1620
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Integra Licox PtO₂ monitor measures oxygen partial pressure (PtO2) and temperature in brain tissue and these parameters are used together as an aid in the determination of the perfusion status of cerebral tissue local to sensor placement. Monitor values are relative within an individual, and should not be used as the sole basis for determining a diagnosis or therapy. It is intended to provide data additional to that obtained by current clinical practice in cases where hypoxia or ischemia are a concern.
Device Description
The Integra® Licox® PtO2 monitor instrument is a diagnostic tool for continuously monitoring oxygen partial pressure (PtO2) in - brain tissue. Minimally invasive probes are implanted directly into the brain tissue and are connected to the Licox monitor. The Integra Licox PtO2 Monitor displays both PtO2 and temperature in numeric format. The monitor will store PtO2 trend data from the most recent 5 days. The user can elect to extract the trend data stored on the monitor to an external memory device or stream the data to a compatible PC via the USB output. The device also provides analog output for display on compatible bedside monitors.
More Information

Not Found

No
The summary describes a device that measures and displays physiological parameters (PtO2 and temperature) and stores/exports trend data. There is no mention of AI, ML, image processing, or any form of algorithmic interpretation or prediction based on the data. The performance studies focus on accuracy, functionality, and safety, not on the performance of any AI/ML model.

No
The device is described as a "diagnostic tool for continuously monitoring oxygen partial pressure (PtO2) in brain tissue." Its intended use states it is an "aid in the determination of the perfusion status of cerebral tissue" and provides "data additional to that obtained by current clinical practice," but it "should not be used as the sole basis for determining a diagnosis or therapy." This indicates it helps in diagnosis, not in providing therapy itself.

Yes

The "Device Description" explicitly states, "The Integra® Licox® PtO2 monitor instrument is a diagnostic tool for continuously monitoring oxygen partial pressure (PtO2) in - brain tissue." Additionally, the "Intended Use / Indications for Use" section mentions it provides data to aid in determining the perfusion status of cerebral tissue, which supports its diagnostic purpose even if it's not the sole basis for diagnosis.

No

The device description explicitly states it is an "instrument" and includes hardware components like a monitor, probes, and connections for data export and analog output. The performance studies also include testing of hardware aspects like electrical safety and environmental testing.

Based on the provided text, the Integra Licox PtO₂ monitor is not an In Vitro Diagnostic (IVD).

Here's why:

  • Definition of IVD: An IVD is a medical device intended for use in the examination of specimens derived from the human body in order to provide information for diagnostic purposes. This typically involves testing samples like blood, urine, tissue biopsies, etc., outside of the body.
  • Device Function: The Integra Licox PtO₂ monitor measures oxygen partial pressure and temperature directly in brain tissue using implanted probes. This is an in vivo measurement, meaning it's performed within the living body.
  • Intended Use: The intended use describes the device as measuring parameters in brain tissue to aid in determining the perfusion status of cerebral tissue local to sensor placement. This is a direct measurement within the body, not an analysis of a specimen taken from the body.

Therefore, because the device performs measurements directly within the brain tissue rather than on a specimen taken from the body, it falls outside the definition of an In Vitro Diagnostic.

N/A

Intended Use / Indications for Use

The Integra Licox PtO2 Monitor measures oxygen partial pressure (PtO2) and temperature in brain tissue and these parameters are used together as an aid in the determination of the perfusion status of cerebral tissue local to sensor placement. Monitor values are relative within an individual, and should not be used as the sole basis for determining a diagnosis or therapy. It is intended to provide data additional to that obtained by current clinical practice in cases where hypoxia or ischemia are a concern.

Product codes

GWM

Device Description

The Integra® Licox® PtO2 monitor instrument is a diagnostic tool for continuously monitoring oxygen partial pressure (PtO2) in - brain tissue. Minimally invasive probes are implanted directly into the brain tissue and are connected to the Licox monitor.

The Integra Licox PtO2 Monitor displays both PtO2 and temperature in numeric format. The monitor will store PtO2 trend data from the most recent 5 days. The user can elect to extract the trend data stored on the monitor to an external memory device or stream the data to a compatible PC via the USB output. The device also provides analog output for display on compatible bedside monitors.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

brain tissue, cerebral tissue

Indicated Patient Age Range

Not Found

Intended User / Care Setting

The operation of the Licox PtO₂ monitor is to be performed by designated qualified hospital staff (i.e. neurosurgeon, nurse, intensivist, trauma physician, physician's assistant, or other appropriately trained staff).

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

The Integra Licox PtO2 monitor was tested in accordance with the relevant test plans/reports included with this 510(k) submission using the production equivalent units.

Testing was performed to ensure that the device met pre-defined performance and safety specifications and to ensure that hazard mitigations functioned as designed.

Testing includes, but is not limited to the following:

  • . PtO2 Accuracy
  • Temperature Accuracy .
  • Alarm setting, accuracy, volume etc. .
  • Trend functionality
  • Data Export Functionality (bedside monitor, external storage) .
  • Fault testing .
  • Electromagnetic Compatibility .
  • Electrical Safety .
  • Environmental Testing .
  • Cleaning Testing .

All necessary testing has been completed for the Integra Licox PtO2 monitor and the test results support the conclusion that all Design Inputs (requirements and specifications) have been met. Testing confirmed that the Integra Licox PtO2 monitor is safe and effective under the proposed conditions of use and is substantially equivalent to the predicate device.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K002765, K040235, K121573, K121159

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 882.1620 Intracranial pressure monitoring device.

(a)
Identification. An intracranial pressure monitoring device is a device used for short-term monitoring and recording of intracranial pressures and pressure trends. The device includes the transducer, monitor, and interconnecting hardware.(b)
Classification. Class II (performance standards).

0

K131184

510(k) Summary

807.92(a)(1) - Submitter Information
NameIntegra LifeSciences Corporation
Address22 Terry Avenue
Burlington, MA 01830
Phone Number(781) 565-1347
Fax Number(781) 238-0645
Establishment Registration Number1222895
Name of Contact PersonElizabeth McMeniman
Date PreparedApril 26, 2013
807.92(a)(2) - Name of device
Trade or Propriety NameIntegra® Licox® PtO2 Monitor
Common or Usual NameIntracranial pressure monitor
Classification NameIntracranial pressure monitoring device
Classification PanelNeurology
RegulationClass II, under 21 CFR 882.1620
Product Code(s)GWM
807.92(a)(3) - Legally marketed device(s) to which equivalence is claimed

LICOX Brain Oxygen Monitoring System, CMP® Monitor and IMC® Systems - K002765 .

  • LICOX PMO BRAIN MONITORING SYSTEM- K040235 .
  • INTEGRA CAMINO ICP MONITOR- K121573 .
  • . INTEGRA CAMINO FLEX VENTRICULAR INTRACRANIAL PRESSURE MONITORING KIT WITH INTRGRA CAMINO FLEX ADAPTER- K121159

807.92(a)(4) - Device description

The Integra® Licox® PtO2 monitor instrument is a diagnostic tool for continuously monitoring oxygen partial pressure (PtO2) in - brain tissue. Minimally invasive probes are implanted directly into the brain tissue and are connected to the Licox monitor.

The Integra Licox PtO2 Monitor displays both PtO2 and temperature in numeric format. The monitor will store PtO2 trend data from the most recent 5 days. The user can elect to extract the trend data stored on the monitor to an external memory device or stream the data to a compatible PC via the USB output. The device also provides analog output for display on compatible bedside monitors.

807.92(a)(5) – Intended Use of the device
Indications for UseThe Integra Licox PtO₂ monitor measures oxygen partial pressure
(PtO2) and temperature in brain tissue and these parameters are used
together as an aid in the determination of the perfusion status of
cerebral tissue local to sensor placement. Monitor values are
relative within an individual, and should not be used as the sole basis
for determining a diagnosis or therapy. It is intended to provide
data additional to that obtained by current clinical practice in cases
where hypoxia or ischemia are a concern.
AUG 3 0 2013

1

Intended UsersThe operation of the Licox PtO₂ monitor is to be performed by designated qualified hospital staff (i.e. neurosurgeon, nurse, intensivist, trauma physician, physician's assistant, or other appropriately trained staff).
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

807.92(a)(6) Summary of the technological characteristics of the device compa predicate

The design of both the modified device and the predicate device are similar. Both of the devices receive signals from the probes that are then translated into the oxygen partial pressure & temperature readings. These readings are then displayed on the screen for the health care practitioners to use as additional information in treatment of the patient.

Integra Licox PrO2 monitor and the predicate device have intended uses, environment for use, device classifications, product codes and measureable parameters as outlined in the substantial equivalence chart and discussion. Any differences in the technological characteristics of the new device do not raise different questions of safety and effectiveness than the predicate device. .

Product CharacteristicsComparison Integra® Licox® PtO₂ Monitor to the predicate
LICOX Brain Oxygen Monitoring System, CMP® Monitor
Parameter Display
PtO2 Trend (5 day) DisplayThe predicate Licox CMP Monitoring System does not trend
PtO2 data.
Trend Data StorageThe predicate Licox CMP Monitoring System does not trend or
store PtO2 data.
Trend Data RetentionThe predicate Licox CMP Monitoring System does not retain
data specific to the probe.
Data OutputThe predicate Licox CMP Monitoring System does not include
a USB port.
System PtO₂ Performance
RequirementsSame
AlarmsThe predicate Licox CMP Monitoring System does not have a
Low PtO2 Alarm or a Low Battery Alarm
Parameter IndicatorsSame
User Inputs via GUI screenThe predicate Licox CMP Monitor used a key pad.
Portability and HandlingThe predicate Licox CMP Monitor cannot be mounted to a pole.
The proposed Licox PtO2 monitor can be mounted to a pole
with diameter between 0.5 and 1.2 inches outer diameter.
Bedside OutputSame
807.92(b)(1-2) - Nonclinical Tests Submitted

The Integra Licox PtO2 monitor was tested in accordance with the relevant test plans/reports included with this 510(k) submission using the production equivalent units.

Testing was performed to ensure that the device met pre-defined performance and safety specifications and to ensure that hazard mitigations functioned as designed.

2

Testing includes, but is not limited to the following:

  • . PtO2 Accuracy
  • Temperature Accuracy .
  • Alarm setting, accuracy, volume etc. .
  • Trend functionality
  • Data Export Functionality (bedside monitor, external storage) .
  • Fault testing .
  • Electromagnetic Compatibility .
  • Electrical Safety .
  • Environmental Testing .
  • Cleaning Testing .

807.92(b)(3) – Conclusions drawn from non-clinical data

All necessary testing has been completed for the Integra Licox PtO2 monitor and the test results support the conclusion that all Design Inputs (requirements and specifications) have been met. Testing confirmed that the Integra Licox PtO2 monitor is safe and effective under the proposed conditions of use and is substantially equivalent to the predicate device.

3

Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles a caduceus, a traditional symbol of medicine, but with a more abstract and modern design.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

August 30, 2013

Integra LifeSciences Corporation % Ms. Elizabeth McMeniman Senior Regulatory Affairs Specialist 311 Enterprise Drive Plainsboro, NJ 08536

Re: K131184

Trade/Device Name: Integra® Licox® PtO2 Monitor Regulation Number: 21 CFR 882.1620 Regulation Name: Intracranial Pressure Monitoring Device Regulatory Class: Class II Product Code: GWM Dated: July 26, 2013 Received: July 29, 2013

Dear Ms. McMeniman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); medical device reporting (reporting of medical

4

Page 2 - Ms. Elizabeth McMeniman

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/Medica]Devices/ResourcesforYou/Industry/default,htm.

Sincerely yours,

Joyce M. Whang -S

for Victor Krauthamer, Ph.D. Acting Division Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

5

Indications for Use

510(k) Number (if known): K131184

Device Name: Integra® Licox® PtO2 Monitor

Indications For Use:

The Integra Licox PtO2 Monitor measures oxygen partial pressure (PtO2) and temperature in brain tissue and these parameters are used together as an aid in the determination of the perfusion status of cerebral tissue local to sensor placement. Monitor values are relative within an individual, and should not be used as the sole basis for determining a diagnosis or therapy. It is intended to provide data additional to that obtained by current clinical practice in cases where hypoxia or ischemia are a concern.

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Joyce M. Whang -S

(Division Sign Off) Division of Neurological and Physical Medicine Devices (DNPMD)

510(k) Number K131184

Page 1 of 1